← Back to Patent Explorer
US4661349A Expired / Lapsed US ⏱️ 0.0 years remaining

Herpes simplex virus subunit vaccine

Assignee: Chemo Sero Therapeutic Research Institute Kaketsuken
•
Filing: 1986-07-09
•
Granted: 1987-04-28
•
Expires: 2006-07-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved herpes simplex virus subunit vaccine being effective against both of HSV type 1 and type 2 and having high safety and high effectiveness, which comprises as an active component a highly purified glycoprotein gB which is a component common to Herpes simplex virus type 1 and type 2, and a method for preparing the herpes simplex virus subunit vaccine and also a lyophilized preparation of the vaccine.

Inventors

  • 👤 Yoichiro Kino
  • 👤 Nobuya Ohtomo

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 16:22
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; C; C07; C07K; C07K14/00; C07K14/005; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16622

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 54 words
A method for preparing a herpes simplex subunit vaccine, which comprises subjecting a solution containing herpes simplex virus glycoproteins to affinity chromatography using as a ligand a monoclonal antibody against herps simplex virus glycoprotein gB, and adsorbing the resulting purified glycoprotein gB onto an aluminum gel to obtain a glycoprotein gB-adsorbed aluminum gel dispersion.
Claim 2
Independent Claim 54 words
A method for preparing a herpes simplex subunit vaccine, which comprises subjecting a solution containing herpes simplex virus glycoproteins to affinity chromatography using as a ligand a monoclonal antibody against herps simplex virus glycoprotein gB, and adsorbing the resulting purified glycoprotein gB onto an aluminum gel to obtain a glycoprotein gB-adsorbed aluminum gel dispersion.
Claim 3
Dependent Claim 47 words
The method according to claim 1, wherein the solution containing herpes simplex virus glycoproteins is a solution obtained by subjecting particles of herpes simplex virus type 1 or type 2 or a virus envelope component of cells infected with the virus to dissolving treatment with a surfactant.
Claim 4
Dependent Claim 63 words
A herpes simplex virus subunit vaccine, which comprises as an essential active component glycoprotein gB produced by the method of subjecting a solution containing herpes simplex virus glycoproteins to affinity chromatography using as a ligand a monoclonal antibody against herpes simplex virus glycoprotein gB, and adsorbing the resulting purified glycoprotein gB onto an aluminum gel to obtain a glycoprotein gB-adsorbed aluminum gel dispersion.
Claim 5
Dependent Claim 63 words
A herpes simplex virus subunit vaccine, which comprises as an essential active component glycoprotein gB produced by the method of subjecting a solution containing herpes simplex virus glycoproteins to affinity chromatography using as a ligand a monoclonal antibody against herpes simplex virus glycoprotein gB, and adsorbing the resulting purified glycoprotein gB onto an aluminum gel to obtain a glycoprotein gB-adsorbed aluminum gel dispersion.
Claim 6
Dependent Claim 47 words
The vaccine according to claim 3, wherein the solution containing herpes simplex virus glycoproteins is a solution obtained by subjecting particles of herpes simplex virus type 1 or type 2 or a virus envelope component of cells infected with the virus to dissolving treatment with a surfactant.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-04-27 1990-10-27 1991-04-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-04-27 1994-10-27 1995-04-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-04-27 1998-10-27 1999-04-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag